​ Virus, Hépatologie, Cancer

Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P, Castaing D, Cherqui D, Irtan S, Calmus Y, Chazouillères O, Soubrane O, Luciani A, Feray C. Living or Brain-dead Donor Liver Transplantation for Hepatocellular Carcinoma: A Multicenter, Western, Intent-to-treat Cohort Study.

CE Costentin, T Decaens, A Laurent, JC Nault, B Paule, C Letoublon, Alain Luciani, Julien Calderaro, R Adam, I Bricault, Giuliana Amaddeo, D Cherqui, A Mallat, D Samuel, C Duvoux, N Ganne-Carrie, F Roudot-Thoraval, E Vibert, Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis

N De'Angelis, S Abdalla, V Lizzi, F Esposito, P Genova, L Roy, F Galacteros, Alain Luciani, F Brunetti, Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy

F Le Gal, Ségolène BRICHLER, T Drugan, C Alloui, D Roulot, Jean-Michel PAWLOTSKY, P Deny, Emmanuel GORDIEN, Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains

C Lim, H Shinkawa, K Hasegawa, P Bhangui, C Salloum, C Gomez Gavara, E Lahat, K Omichi, J Arita, Y Sakamoto, P Compagnon, Cyrille FERAY, N Kokudo, D Azoulay, Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis

M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, JK Albrecht, P Schmid, F Le Gal, Emmanuel GORDIEN, A Krawczyk, H Mijocevic, H Karimzadeh, M Roggendorf, A Vaillant, Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, M Backmund, P Bruggmann, O Dalgard, C Seguin-Devaux, R Flisiak, GR Foster, L Gheorge, D Goldberg, I Goulis, M Hickman, P Hoffmann, L Janconriene, P Jarcuska, M Kaberg, LG Kostrikis, M Makara, M Maimets, RT Marinho, M Maticic, S Norris, S Olafsson, A Ovrehus, Jean-Michel PAWLOTSKY, J Pocock, G Robayes, C Roncero, M Simonova, J Sperl, M Tait, I Tolmane, S Tomaselli, M van der Valk, A Vince, GJ Dore, JV Lazarus, J Grebely, International Network on Hepatitis in Substance Users (INHSU), Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

S Mule, F Pigneur, R Quelever, A Tenenhaus, L Baranes, P Richard, Vania TACHER, E Herin, H Pasquier, M Ronot, A Rahmouni, V Vilgrain, Alain LUCIANI, Can dual-energy CT replace perfusion CT for the functional evaluation of advanced hepatocellular carcinoma?

A Brown, Christophe HEZODE, E Zuckerman, GR Foster, A Zekry, SK Roberts, F Lahser, C Durkan, C Badshah, B Zhang, M Robertson, J Wahl, E Barr, B Haber, C-SCAPE Study Investigators, Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study

F Poordad, S Pol, A Asatryan, M Buti, D Shaw, Christophe HEZODE, F Felizarta, RW Reindollar, SC Gordon, S Pianko, MW Fried, D Bernstein, J Gallant, CW Lin, Y Lei, TI Ng, P Krishnan, S Kopecky-Bromberg, J Kort, FJ Mensa, Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure